Wegovy received FDA approval in 2024 to reduce the risk of heart attack, stroke, and cardiovascular death in overweight or obese adults with established heart disease
Unlike native GLP-1, which has a half-life of only 1-2 minutes due to rapid enzymatic cleavage, the unique lipidization of the Semaglutide Peptide allows it to strongly bind to serum albumin, facilitating a substantially prolonged half-life for extended observational studies
These agents enhance glucose-dependent insulin secretion from pancreatic beta cells, suppress inappropriate glucagon release, slow gastric emptying, and promote satiety through central nervous system pathways
For athletes, losing hard earned muscle mass can be problematic
Ozempic is the brand name prescribed for diabetes and Wegovy is the brand name for weight loss